Fig. 3

a Absolute methylation levels of LIN7A, BASP1, EMB, and CEBPA in t(8;21) AML patients were higher than those in non-t(8;21) AML patients. b Absolute methylation levels of LIN7A, BASP1, EMB and CEBPA in de novo samples were higher than those in CR samples. c Distribution of CpG islands in the promoter region of the four genes. d Expression of LIN7A was much lower in patients with the t(8;21) translocation compared with that in other karyotypes according to TCGA dataset. e The expression levels of LIN7A positively correlated with the overall survival rate of AML patients. f LIN7A, BASP1, and EMB were identified as methylated genes in t(8;21) AML patients according to the GSE18700 dataset. g The methylation levels of LIN7A-probe 3 targeted sequence were significantly higher in patients with t(8;21) AML. h–i The methylation levels of the LIN7A-probe 3 targeted sequence negatively correlated with the h overall and i event-free survival rates of patients with t(8;21) AML. j Quantitative real-time polymerase chain reaction and k western blotting analyses showed increased mRNA and protein levels of LIN7A after treatment with 10 nM DAC for three (DAC-T3) or seven (DAC-T7) consecutive days. l Methylation-specific PCR of Kasumi-1 cells showed methylation of the probe 3-targeted sequence by two different paired primers. m LIN7A expression analysis determined by qRT-PCR after treatment with shLIN7A lentiviruses accompanied with or without 10 nM DAC in Kasumi-1 and SKNO-1 cells. n Western blot analysis of LIN7A expression change after treatment with shLIN7A lentiviruses accompanied with or without 10 nM DAC in Kasumi-1 and SKNO-1 cells. DMR Differentially methylated region; DAC Decitabine. *p < 0.05, **p < 0.01, and ***p < 0.001